West Pharmaceutical Services reported strong Q2 results, beating revenue and EPS estimates. The company saw 9.2% revenue growth to $766.5 million and a 22% beat in adjusted EPS. Management highlighted demand for GLP-1 elastomer products and growth in HVP components. Analyst questions during the earnings call focused on product growth, destocking, guidance raise reasons, growth strategies, and labor constraints in Europe. The company raised full-year revenue and EPS guidance, with a focus on higher-margin businesses. Key upcoming catalysts include Annex-1 upgrades, labor constraints resolution, and demand trends. Stock currently trades at $246.42.

Are you considering buying or selling WST? Check out the full research report to make an informed decision.

If you’re looking for high-quality stocks for all market conditions, explore the Top 5 Strong Momentum Stocks list curated by StockStory. These stocks have generated a market-beating return of 183% over the last five years. StockStory is also hiring equity analyst and marketing roles for passionate individuals interested in AI and the markets.

Read more at StockStory: The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call